Good morning friends and fellow traders, and welcome to the second trading week of the new year! As we mentioned in Friday's edition of the newsletter, we're kicking off the week with a new trading idea we think you're going to love.
Simply put, this company is in the right place at the right time with the right product. How so? It melds wearables -- the hottest of the market's hot buttons right now -- with medical-grade monitoring technology. To put it bluntly, this outfit does what Fitbit should have been trying to do, but didn't. That company is called CardioComm Solutions Inc. (EKGGF, CVE:EKG).
In the interest of time, we chose to give you the abbreviated version of the stock's story, but do know the SmallCap Network has prepared a more robust research report on CardioComm. It'll be available at the site later today.
Good Friday afternoon folks, or for some of you good Saturday morning (or maybe even good Monday morning). Whenever it is you get to read our newsletter, you probably don't need me to tell you the Dow Jones Industrial Average fell just a bit short of the 20,000 mark on Friday. It wasn't from a lack of trying though. In the meantime, the NASDAQ as well as the S&P 500 both managed to move to record levels.
We'll look at it all in a moment, along with a detailed look at all the jobs numbers - as is always the case, the media did a poor job of telling you everything you needed to know. Before we get to any of that, however, we want to give you a heads-up.... on Monday morning we'll be sending a new small cap trading idea your way.
Howdy folks. How was your Thursday? It wasn't so hot for stocks, though it could have been worse. The bulls clearly aren't ready to take the leap back into record-high territory. That's ok though. It's not like the bears did any real damage to the broader uptrend. Mostly we're still on hold, market-wise, which means we all need to be focused on trading individual stocks that are actually moving rather than waiting for the marketwide tide to lift all boats.
On that note, we do have a little trading business to take care of...
You may or may not remember it, but back on August 19th we made a completely-unofficial trading suggestion of magicJack VocalTec (CALL). Actually, it was an idea we "borrowed" from the Under the Radar Movers service, which had suggested the trade a few days prior to our recommendation. Whatever the case, if you got into CALL on our recommendation and have stuck it out this far, we now recommend you lock in your 37% gain on the position by selling it. It looks as if magicJack is at a near-term peak.
Good Wednesday afternoon, everybody. How are things? If you're a regular reader of the website and act on the trading ideas we share with you from time to time, then you've got to be pretty happy with the way Lexaria Bioscience (LXRP) performed today. On the other hand, if you're a member of the Under the Radar Movers service, you also had a big day on Wednesday, as your newest pick was also catapulted skyward today shortly after that recommendation was sent out.
We're going to give you that pick today -- as a freebie -- but first let's show you Lexaria.
In case you don't recall (or you're new), Lexaria Bioscience has developed a way to improve a body's absorption of hemp oil, or specifically, cannabidiol. The plant-based edible/ingestible offers some amazing health benefits. Problem is, the body doesn't readily absorb all the cannabidiol a person ingests.
Welcome to the new year, friends and fellow traders. Though we ended up giving back some of our intraday gains and we closed on the fence, so to speak, at least stocks got 2017 started on a bullish foot.
Since it's that time of year, today we're going to devote some time to the so-called January effect and decide how much impact (if any at all) the first few days of the year has on the remainder of the year. The reality may surprise you.
First though, let's take a look at the one and only news item we had from our stable of Featured Stocks at the website. Staffing 360 Solutions (STAF) got the new year going with an impressive -- though not surprising -- preliminary look at last quarter's results.